Nearly a quarter of the children participating in a clinical study for CooperVision’s MiSight 1 day contact lenses experienced no myopia progression after six years, according to the latest findings.
“Evaluating children who were prescribed MiSight 1 day at the study’s initiation, 23 per cent of eyes after Year 6 displayed a total refractive change of less than -0.25D (spherical equivalent), which could be considered clinically stable,” says Paul Chamberlain, CooperVision’s director of research programs.
“There is now even more reason to recognize the substantial capability of this unique dual-focus contact lens.”
CooperVision shared the latest findings of its clinical study in the fall during the American Academy of Optometry’s virtual annual meeting.
The findings also suggested that while intervention at an early age is optimal with MiSight 1 day, starting treatment at an older age can similarly slow the rate of myopia progression.
The original control group was refit into the dual-focus lens in Year 4. Comparing this population to the children fit with MiSight 1 day at initiation, there have been similar rates of myopia progression and axial length growth in the subsequent three years of assessment, CooperVision says.
In addition, the six-year results continued to demonstrate excellent safety profile, wearing time and visual acuity for children in daily disposable contact lenses over 653 wearing years. No other prospective randomized controlled study has offered conclusive data for such a high degree of continued efficacy in myopia management using a soft contact lens over a similar time span.
